3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
3
Unknown
2
Not yet recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Sarcoma
1
Conditions
Carcinoma, Basal Cell
2
Sarcoma, Kaposi
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Interventions
Cisplatin
509
Cyclophosphamide
360
Carboplatin
352
Radiotherapy
350
Capecitabine
329
Paclitaxel
325
Oxaliplatin
324
Gemcitabine
319
Docetaxel
311
Fluorouracil
283
Drug Therapy
243
apatinib
242
Bevacizumab
229
camrelizumab
214
Etoposide
200
Irinotecan
176
Doxorubicin
175
Leucovorin
161
Dexamethasone
160
sintilimab
142
pembrolizumab
138
anlotinib
136
Pemetrexed
136
Cytarabine
136
toripalimab
129
Neoadjuvant Therapy
122
S 1 (combination)
120
Vincristine
119
Rituximab
117
Radiosurgery
117
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Unknown
×
Interventional
×
daromun
×
Clear all
NCT04362722
2023-10-10
DUNCAN
Philogen S.p.A.
Phase 2
Unknown
40 enrolled
NCT05329792
2023-10-06
IntriNSiC
Philogen S.p.A.
Phase 2
Unknown
70 enrolled